Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Bernard Jandrain is active.

Publication


Featured researches published by Bernard Jandrain.


Nutrients | 2015

A Randomized, Double-Blind, Parallel Study to Evaluate the Dose-Response of Three Different Vitamin D Treatment Schemes on the 25-Hydroxyvitamin D Serum Concentration in Patients with Vitamin D Deficiency

Marie-Louise Schleck; Jean-Claude Souberbielle; Bernard Jandrain; Stéphanie Da Silva; Sophie De Niet; Francis Vanderbist; André Scheen; Etienne Cavalier

Many people worldwide are vitamin D (VTD) deficient or insufficient, and there is still no consensus on the dose of VTD that should be administered to achieve a 25(OH)D concentration of 20 or 30 ng/mL. In this study, we aimed to determine an adapted supplementation of VTD able to quickly and safely increase the vitamin D status of healthy adults with low 25(OH)D. One hundred and fifty (150) subjects were randomized into three groups, each to receive, orally, a loading dose of 50,000, 100,000 or 200,000 IU of VTD3 at Week 0, followed by 25,000, 50,000 or 100,000 IU at Week 4 and Week 8. Whereas 25(OH)D baseline values were not different between groups (p = 0.42), a significant increase was observed at Week 12 (p < 0.0001) with a mean change from baseline of 7.72 ± 5.08, 13.3 ± 5.88 and 20.12 ± 7.79 ng/mL. A plateau was reached after eight weeks. No related adverse event was recorded. This study demonstrated a linear dose-response relationship with an increase in 25(OH)D levels proportional to the dose administered. In conclusion, a loading dose of 200,000 IU VTD3 followed by a monthly dose of 100,000 IU is the best dosing schedule to quickly and safely correct the VTD status.


Nutrients | 2016

A Randomised, Cross-Over Study to Estimate the Influence of Food on the 25-Hydroxyvitamin D3 Serum Level after Vitamin D3 Supplementation

Etienne Cavalier; Bernard Jandrain; Monte Coffiner; Stéphanie Da Silva; Sophie De Niet; Francis Vanderbist; Jean-Claude Souberbielle

Vitamin D3 is known to be liposoluble and its release could be a factor limiting the rate of absorption. It was presumed that the presence of fat could favor absorption of vitamin D3. However, as bioavailability is related not only to the active molecules but also to the formulations and excipients used, the optimization of the pharmaceutical form of vitamin D3 is also important. The objective of this study was to evaluate if there is a food effect on absorption when a high dose of vitamin D3 is completely solubilized in an oily solution. In the present cross-over study, 88 subjects were randomized and received a single dose of 50,000 IU of vitamin D3 in fasting state or with a standardized high-fat breakfast. Assessment of serum concentrations of 25 hydroxyvitamin D3 (25(OH)D3) was performed three, five, seven, 14, 30 and 60 days after supplementation. In fed and fast conditions, the 25(OH)D3 serum concentrations were significantly higher than the baseline value three days after administration and remained significantly higher during the first month. No significant difference between fasting vs. fed conditions was observed. It is therefore concluded that the vitamin D3 absorption from an oily solution was not influenced by the presence or absence of a meal.


Nutrients | 2018

A Randomized Study to Compare a Monthly to a Daily Administration of Vitamin D3 Supplementation

Sophie De Niet; Monte Coffiner; Stéphanie Da Silva; Bernard Jandrain; Jean-Claude Souberbielle; Etienne Cavalier

We aimed to determine whether a cumulative dose of vitamin D3 produces the same effects on the serum concentration of 25(OH)D3 if it is given daily or monthly. This is a monocentric, two-armed, randomized, interventional, open, and parallel study conducted from November 2016 to March 2017 in Belgium. We randomized 60 subjects with vitamin D deficiency to receive 2000 IU vitamin D3 daily or 50,000 IU monthly. The same cumulative dose of vitamin D3 was given to each treatment group (150,000 IU). The 25(OH)D3 serum concentrations from baseline to day 75 were 14.3 ± 3.7 to 27.8 ± 3.9 ng/mL in the monthly group and 14.1 ± 3.4 to 28.8 ± 5.4 ng/mL in the daily group. The mean change versus the baseline level was significantly different between the groups at day 2, 4, 7, and 14 and no longer different from day 25. One day after the intake of vitamin D3, as expected, serum 25(OH)D3 and 1,25(OH)2D3 increased significantly in the monthly group, whereas they did not change significantly in the daily group. The median time to reach the 20 ng/mL target concentration was significantly different in the two groups, in favor of the monthly regimen (1 day versus 14 days; p = 0.02). In conclusion, a monthly administration of 50,000 IU vitamin D3 provides an effective tool for a rapid normalization of 25(OH)D3 in deficient subjects. A daily administration of the same cumulative dose is similarly effective but takes two weeks longer to reach the desirable level of 20 ng/mL.


Revue médicale de Liège | 2003

Alcool, sensibilite a l'insuline et diabete sucre.

Delphine Magis; Bernard Jandrain; André Scheen


Revue médicale de Liège | 2008

L'etude clinique du mois. Controle glycemique et morbimortalite cardio-vasculaire chez le patient diabetique de type 2. Resultats des etudes ACCORD, ADVANCE et VA-Diabetes.

Régis Radermecker; Jean-Christophe Philips; Bernard Jandrain; Nicolas Paquot; André Scheen


International Journal of Obesity | 1994

Relationships between metabolic clearance rate of insulin and body mass index in a female population ranging from anorexia nervosa to severe obesity.

Manuel J. Castillo; André Scheen; Bernard Jandrain; Pierre Lefebvre


Revue médicale de Liège | 2002

Comment j'explore ... Le risque d'un patient d'evoluer vers un diabete de type 2.

André Scheen; Nicolas Paquot; Bernard Jandrain


Revue médicale de Liège | 2001

[Multidisciplinary management of the obese patient: example from the Obesity Center at the University of Liege].

André Scheen; Marcelle Rorive; Michel Letiexhe; Devoitille L; Bernard Jandrain


Medecine Et Hygiene | 2002

Approches pharmacologiques de prévention du diabète de type 2.

André Scheen; Nicolas Paquot; Michel Letiexhe; Bernard Jandrain


Revue médicale de Liège | 2010

Stratégies pour éviter l'inertie et la non-observance dans les essais cliniques

Bernard Jandrain; Philippe Ernest; Régis Radermecker; André Scheen

Collaboration


Dive into the Bernard Jandrain's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Jean-Claude Souberbielle

Necker-Enfants Malades Hospital

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge